MK
Murali Krishna Madala
About Murali Krishna Madala
Data last updated:
Murali Krishna Madala is a Managing Director at Apicore Pharmaceuticals Private Limited (since 2018), Designated Partner at 4C Drug Safety Services Llp (since 2015) and Designated Partner at Aktinos Biologics Llp (since 2025), and holds 1 more current directorship. The companies operate in Pharma, Biotechnology and Wood. The 2 current companies with reported revenue have a combined latest revenue of ₹211 Cr; the largest is Apicore Pharmaceuticals Private Limited at ₹195 Cr (FY 2024). Earlier, Murali Krishna Madala was a Director at Vijayasri Organics Private Limited (2005–2007) and Director at S.V.R. Laboratories Private Limited (2008–2015) and 3 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Apicore Pharmaceuticals Private Limited U24119GJ2006FTC048777 | Managing Director | 21 May 2018 | 2006 | ₹195 Cr (FY 2024) | Active |
 4C Drug Safety Services Llp AAD-3419 | Designated Partner | 11 Feb 2015 | 2015 | ₹15.76 Cr (FY 2023) | Active |
| Aktinos Biologics Llp ACT-1671 | Designated Partner | 03 Dec 2025 | 2025 | Active | |
| Sr Generics Private Limited U20290TS2024PTC187648 | Director | 18 Jul 2024 | 2024 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Vijayasri Organics Private Limited U24239TG2005PTC047307 | Director | 31 Aug 2005 | 2005 | ₹280 Cr (FY 2025) | Active |
| S.V.R. Laboratories Private Limited U24239TG2003PTC041653 | Director | 12 Jun 2008 | 2003 | ₹44.45 Cr (FY 2025) | Active |
 Omgene Life Sciences Private Limited U24230GJ2011PTC064483 | Director | 06 Jan 2014 | 2011 | ₹30.12 Cr (FY 2025) | Active |
 Aktinos Pharma Private Limited U24232TG2007PTC055510 | Managing Director | 13 Sep 2007 | 2007 | ₹208 Cr (FY 2024) | Amalgamated |
 Aktinos Healthcare Private Limited U85100AP2010PTC070469 | Managing Director | 16 Sep 2010 | 2010 | ₹42.58 Cr (FY 2017) | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Murali Krishna Madala
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anjali Hemant Prasad | Apicore Pharmaceuticals Private Limited | Company Secretary | |
| Jayaraman Kannappan | 07016114 | Apicore Pharmaceuticals Private Limited | Whole-Time Director |
| Mahesh Suresh Javale | 10390685 | Apicore Pharmaceuticals Private Limited | Nominee Director |
| Parthiv Patel | 07876985 | Apicore Pharmaceuticals Private Limited | Director |
| Ravishanker Kovi | 00278107 | Apicore Pharmaceuticals Private Limited | Director |
| Yathendra Kumar Madineni | 07025215 | 4C Drug Safety Services Llp | Designated Partner |
| Srilakshmi Madala | 01746196 | Aktinos Biologics Llp | Designated Partner |
| Venkata Ravi Kumar Vasireddy | 02042456 | Sr Generics Private Limited | Director |
| Venu Gopala Reddy Marella | 10711165 | Sr Generics Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Murali Krishna Madala
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Murali Krishna Madala
Murali Krishna Madala currently holds 4 directorships: Apicore Pharmaceuticals Private Limited (Managing Director, since 21 May 2018, revenue ₹195 Cr (FY 2024)); 4C Drug Safety Services Llp (Designated Partner, since 11 Feb 2015, revenue ₹15.76 Cr (FY 2023)); Aktinos Biologics Llp (Designated Partner, since 03 Dec 2025); Sr Generics Private Limited (Director, since 18 Jul 2024).
Murali Krishna Madala was first appointed on 31 Aug 2005 as Director at Vijayasri Organics Private Limited. The most recent appointment on record is 03 Dec 2025 at Aktinos Biologics Llp.
The 2 current companies of Murali Krishna Madala that report revenue have a combined latest revenue of ₹211 Cr: Apicore Pharmaceuticals Private Limited ₹195 Cr (FY 2024); 4C Drug Safety Services Llp ₹15.76 Cr (FY 2023).
Murali Krishna Madala held 5 earlier board appointments: Vijayasri Organics Private Limited (Director, 31 Aug 2005 to 12 Sep 2007); S.V.R. Laboratories Private Limited (Director, 12 Jun 2008 to 10 Dec 2015); Omgene Life Sciences Private Limited (Director, 06 Jan 2014 to 02 Sep 2016); Aktinos Pharma Private Limited (Managing Director, from 13 Sep 2007); Aktinos Healthcare Private Limited (Managing Director, from 16 Sep 2010).
The current boards of Murali Krishna Madala's companies include Anjali Hemant Prasad (Apicore Pharmaceuticals Private Limited), Jayaraman Kannappan (Apicore Pharmaceuticals Private Limited), Mahesh Suresh Javale (Apicore Pharmaceuticals Private Limited), Parthiv Patel (Apicore Pharmaceuticals Private Limited), Ravishanker Kovi (Apicore Pharmaceuticals Private Limited), Yathendra Kumar Madineni (4C Drug Safety Services Llp), among others.